Osmotica Pharmaceuticals PLC (OSMT)
Stock Price:
$8.77 USD
1.77 (25.29%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
After-hours: $8.74 -0.03 (-0.34%) Jul 10, 7:58 PM
Key Info
| Market Cap |
516.54M |
| Revenue (ttm) |
231.55M |
| Net Income (ttm) |
-267.08M |
| Shares Out |
58.90M |
| EPS (ttm) |
-4.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$8.77 |
| Previous Close |
$7.00 |
| Change ($) |
1.77 |
| Change (%) |
25.29% |
| Day's Open |
7.10 |
| Day's Range |
7.00 - 9.67 |
| Day's Volume |
4,737,222 |
| 52-Week Range |
2.70 - 9.67 |
More Stats
| Market Cap |
516.54M |
| Enterprise Value |
663.74M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
58.90M |
| Float |
11.09M |
| EPS (basic) |
-5.09 |
| EPS (diluted) |
-4.97 |
| FCF / Share |
0.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
6.83% |
| Payout Ratio |
n/a |
| Shares Short |
868,198 |
| Short Ratio |
1.49 |
| Short % of Float |
5.11% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
14.63 |
| PS Ratio |
2.23 |
| PB Ratio |
2.58 |
| Revenue |
231.55M |
| Operating Income |
-276.00M |
| Net Income |
-267.08M |
| Free Cash Flow |
35.30M |
| Net Cash |
-147.20M |
| Net Cash / Share |
-2.50 |
| Gross Margin |
55.45% |
| Operating Margin |
-119.20% |
| Profit Margin |
-115.30% |
| FCF Margin |
15.24% |
| ROA |
0.77% |
| ROE |
-101.83% |
| ROIC |
-87.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.00*
(-8.78% downside)
Low
4.00
Current: 8.77
High
10.00
Target: 8.00
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 240 | 264 | 246 | 218 |
| Revenue Growth | -8.98% | 7.31% | 12.49% | - |
| Gross Profit | 128 | 124 | 121 | 92.84 |
| Operating Income | -281 | -98.54 | -52.07 | -32.05 |
| Net Income | -271 | -110 | -41.14 | -41.82 |
| Shares Outstanding | 52.37 | 45.28 | 42.86 | 1.00 |
| Earnings Per Share | -5.17 | -2.42 | -0.96 | -41.81 |
| Operating Cash Flow | 33.57 | 37.56 | 57.84 | -44.79 |
| Capital Expenditures | -4.02 | -4.13 | -6.90 | -13.93 |
| Free Cash Flow | 29.55 | 33.42 | 50.94 | -58.72 |
| Cash & Equivalents | 95.87 | 70.83 | 34.74 | 19.56 |
| Total Debt | 273 | 269 | 321 | 329 |
| Net Cash / Debt | -177 | -198 | -286 | -309 |
| Assets | 463 | 796 | 920 | 979 |
| Liabilities | 349 | 412 | 484 | 513 |
| Book Value | 115 | 384 | 436 | 465 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Osmotica Pharmaceuticals PLC |
| Country |
United States |
| Employees |
379 |
| CEO |
Brian A. Markison |
Stock Information
| Ticker Symbol |
OSMT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: OSMT |
Description
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.